Priebeh ochorenia u pacientov s diferencovaným mikrokarcinómom štítnej žľazy pri použití rôznych liečebných postupov
[The course of differentiated thyroid microcarcinoma in patients treated by different therapeutic strategies]
Jazyk čeština Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
27734686
PII: 59221
- MeSH
- adjuvantní radioterapie MeSH
- krční disekce * MeSH
- kvalita života MeSH
- lidé MeSH
- nádory štítné žlázy patologie terapie MeSH
- papilární karcinom patologie terapie MeSH
- prognóza MeSH
- radioizotopy jodu terapeutické užití MeSH
- riziko MeSH
- společnosti lékařské MeSH
- staging nádorů MeSH
- tyreoidektomie * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- radioizotopy jodu MeSH
Low risk differentiated thyroid microcarcinoma therapy is a controversial area of thyroid tumor management. Major international medical societies and reputable institutes consider lobectomy to be sufficient therapeutic intervention for the pT1a cN0cM0 stage of papillary thyroid microcarcinoma. However different views and therapeutic strategies exist and result in unnecessary overtreatment and worsening of patients quality of life. We researched the course of the differentiated thyroid microcarcinoma in patients using different therapeutic strategies: lobectomy, total thyroidectomy, total thyroidectomy with central compartment prophylactic lymphadenectomy and total thyroidectomy followed by radioactive iodine treatment. Apart from an excellent prognosis we did not find out any clinically significant differences in the course of the disease. We can conclude that lobectomy is sufficient therapeutic intervention for patients with differentiated thyroid microcarcinoma without known metastases.Key words: differentiated thyroid microcarcinoma - management - overtreatment - the course of the disease.
